INT36237

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 1987
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 2.31
Pain Relevance 4.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Ass1) endoplasmic reticulum (Ass1) nucleus (Ass1)
ligase activity (Ass1) lysosome (Ass1) cytoplasm (Ass1)
Anatomy Link Frequency
skin 1
lungs 1
Ass1 (Mus musculus)
Pain Link Frequency Relevance Heat
Enkephalin 7 99.36 Very High Very High Very High
tolerance 12 99.04 Very High Very High Very High
Analgesic 6 98.84 Very High Very High Very High
Potency 3 98.54 Very High Very High Very High
Delta opioid receptors 1 97.04 Very High Very High Very High
agonist 34 96.32 Very High Very High Very High
Desipramine 1 96.12 Very High Very High Very High
opioid receptor 5 95.96 Very High Very High Very High
Morphine 4 94.96 High High
narcan 10 94.56 High High
Disease Link Frequency Relevance Heat
Adenoma 3 99.36 Very High Very High Very High
Reprotox - General 2 2 98.54 Very High Very High Very High
Targeted Disruption 43 96.24 Very High Very High Very High
Fibrosis 106 93.04 High High
Cancer 10 89.36 High High
Severe Combined Immunodeficiency 6 76.16 Quite High
Intestinal Cancer 1 74.32 Quite High
Lymphatic System Cancer 1 73.56 Quite High
Sprains And Strains 4 72.16 Quite High
Colon Cancer 3 65.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
governs metabolism of amino acids by suppressing expression of genes involved in transamination (Aspartate amino transferase (Got1), Alanine amino transferase (Gpt), Alanine glyoxylate aminotransferase (Agtx2), and deamination (Glutaminase (Gls)), as well as numerous genes that are part of the urea cycle (Cps1, Otc, Ass1, and Asl) [160, 161, 245].
Gene_expression (expression) of Ass1
1) Confidence 0.24 Published 2010 Journal PPAR Research Section Body Doc Link PMC2948931 Disease Relevance 0 Pain Relevance 0.14
Seven injections of Delta(9)-THC (3.5 days of dosing) resulted in a 12-fold and 36-fold decrease in potency, respectively, while 13 injections of Delta(9)-THC (6.5 days of dosing) produced a 6.2-fold and 9.8-fold degree of tolerance.
Gene_expression (produced) of 6.2-fold associated with reprotox - general 2, tolerance and potency
2) Confidence 0.12 Published 2000 Journal Drug Alcohol Depend Section Abstract Doc Link 10940538 Disease Relevance 0.19 Pain Relevance 0.80
DAGO (D-ala2, MePhe4, Gly-ol5 enkephalin), a highly mu selective agent, produced a 67-fold difference between HAR and LAR mice in the slopes of the dose-response curves on the hot plate assay, while DSLET (D-ser2, leu enkephalin Thr6), a delta selective agent, only produced a 5.4-fold difference via the i.c.v. route.
Gene_expression (produced) of 67-fold associated with enkephalin
3) Confidence 0.06 Published 1987 Journal Life Sci. Section Abstract Doc Link 3298912 Disease Relevance 0.07 Pain Relevance 1.11
The transgene produced high mRNA levels (375-fold over endogenous).
Gene_expression (produced) of 375-fold
4) Confidence 0.02 Published 2007 Journal Cancer Res. Section Abstract Doc Link 17283118 Disease Relevance 1.18 Pain Relevance 0.09
Tyr-W-MIF-1, producing a 3.1-fold leftward shift in the dose-response curve.
Gene_expression (producing) of 3.1-fold
5) Confidence 0.02 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8846821 Disease Relevance 0 Pain Relevance 1.33
Only genes with more than 1.5-fold expression differences between control and c-Met mutant mice in at least 80% of samples were included in the list of significant genes.
Gene_expression (expression) of 1.5-fold
6) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2940888 Disease Relevance 0 Pain Relevance 0
Importantly, the PAR bZip genes control expression of two genes essential for xenobiotic metabolism: aminolevulinic acid synthase (ALAS1) and POR, with a 2.0-fold and 2.9-fold higher expression in GF mice respectively [22].
Gene_expression (expression) of 2.0-fold
7) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2734986 Disease Relevance 0 Pain Relevance 0
Similarly, Ctgf siRNA also reduced SPARC expression in skin and lungs (2.9-fold and 1.5-fold reduction with P = 0.044 and 0.102, respectively).


Gene_expression (expression) of 2.9-fold in skin
8) Confidence 0.01 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888211 Disease Relevance 0.33 Pain Relevance 0.12
Con A (20 micrograms/ml) significantly increased the Bmax (3.5-fold; expressed per cell) and resulted in a loss of the higher-affinity site.
Gene_expression (expressed) of 3.5-fold
9) Confidence 0.01 Published 1994 Journal Immunopharmacology Section Abstract Doc Link 7852049 Disease Relevance 0.14 Pain Relevance 0.66
Rifampicin treatment enhanced the expression of h-CYP3A4 by 5.8-fold, but did not affect the levels of the other five h-CYPs.
Gene_expression (expression) of 5.8-fold
10) Confidence 0.01 Published 2009 Journal PPAR Research Section Body Doc Link PMC2768028 Disease Relevance 0.08 Pain Relevance 0
Similarly, Ctgf siRNA also reduced SPARC expression in skin and lungs (2.9-fold and 1.5-fold reduction with P = 0.044 and 0.102, respectively).


Gene_expression (expression) of 2.9-fold in lungs
11) Confidence 0.00 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888211 Disease Relevance 0.33 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox